Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mai A. Samir"'
Publikováno v:
The Egyptian Journal of Hospital Medicine. 90:3143-3146
Publikováno v:
The Egyptian Journal of Hospital Medicine. 87:1204-1207
Publikováno v:
The Egyptian Journal of Hospital Medicine. 88:2472-2474
Publikováno v:
The Egyptian Journal of Hospital Medicine. 87:1599-1601
Botulinum toxin type‐A versus 5‐fluorouracil in the treatment of plaque psoriasis: Comparative study
Autor:
Mai A. Samir, Fathia M Khattab
Publikováno v:
Journal of Cosmetic Dermatology. 20:3128-3132
BACKGROUND Long-term remission and total clearance in Psoriasis can only be achieved in a few patients. AIM To compare the efficacy and safety of intradermal Botulinum toxin (BTX) in the treatment of plaque psoriasis. SUBJECTS AND METHODS A comparati
Publikováno v:
The Egyptian Journal of Hospital Medicine. 81:1840-1844
Background: Psoriasis is a chronic, immune-mediated, systemic inflammatory disease that is defined by a characteristic skin reaction produced when elevated levels of inflammatory cytokines that alter the growth and differentiation of skin cells. Tumo
Autor:
Mai A. Samir, Fathia M Khattab
Publikováno v:
Journal of Cosmetic Dermatology. 19:3389-3392
Background Neopterin is a cellular immunity biochemical marker. Serum and saliva neopterin levels have been reported to increase in lichen Planus. Nonetheless, analysis has not yet been made for the direct link between narrow band ultraviolet B and s
Autor:
Fathia M Khattab, Mai A. Samir
Publikováno v:
Journal of Cosmetic Dermatology. 19:2428-2431
Background Keloids are dermal fibroproliferative disorders that characterized by over deposition of components of the extracellular matrix. Interleukin 37 (IL-37) is known by its ability to inhibit the proliferation of keloid fibroblasts by inhibitin
Autor:
Mai A. Samir, Fathia M Khattab
Publikováno v:
Journal of Cosmetic Dermatology. 19:1780-1784
BACKGROUND Lichen planus (LP) is an autoinflammatory mucocutaneous skin disorder with a multifactorial pathogenesis. Squamous cell carcinoma antigen (SCCA) is a tumor marker recognized as a part of the ovalbumin-serpin family. In patients' serum and